

## Electronic Supporting information

# Access to functionalized luminescent Pt(II) complexes by photoredox-catalyzed Minisci alkylation of 6-aryl-2,2'-bipyridines

Wided Hagui,<sup>a</sup> Marie Cordier,<sup>a</sup> Julien Boixel<sup>\*a</sup> and Jean-François Soulé<sup>\*a</sup>

<sup>a</sup> Univ Rennes, CNRS UMR6226, F-3500 Rennes, France.

Emails : [julien.boixel@univ-rennes1.fr](mailto:julien.boixel@univ-rennes1.fr), [jean-francois.soule@univ-rennes1.fr](mailto:jean-francois.soule@univ-rennes1.fr)

### Table of contents

1. GENERAL INFORMATION .....	2
2. PROCEDURE FOR THE SYNTHESIS OF NHPI REDOX-ACTIVE ESTERS & PRODUCT CHARACTERIZATIONS .....	3
3. PROCEDURE FOR PHOTO PHOTOREDOX-CATALYZED MINISCI-TYPE ALKYLATION OF 6-ARYL-2,2'-BIPYRIDINES & PRODUCT CHARACTERIZATIONS .....	7
4. PROCEDURE FOR THE PREPARATION OF CYCLOMETALATED PT(II) CHLORIDE COMPLEXES & PRODUCT CHARACTERIZATIONS .....	13
5. PROCEDURE FOR THE PREPARATION OF ALKYNYL CYCLOMETALATED PT(II) COMPLEXES & PRODUCT CHARACTERIZATIONS .....	18
6. X-RAY CRYSTALLOGRAPHIC DATA .....	21
7. ADDITIONAL PHOTOPHYSICAL DATA .....	22
8. REFERENCES .....	25
9. COPY OF THE NMR SPECTRUM .....	25

## 1. General information

All reactions were carried out under argon atmosphere with standard Schlenk techniques. All reagents were obtained from commercial sources and used as supplied. All reactions were performed using dry and degassed solvents unless stated otherwise. Toluene was purified by passage through activated alumina using a Glass Contour Solvent Dispensing System. Technical grade heptane and ethyl acetate were used for column chromatography.

All reagents were weighed and handled in air.

$^1\text{H}$ , and  $^{13}\text{C}$  NMR spectra were recorded on Bruker AV III 400 MHz NMR spectrometer equipped with BBFO probehead. Chemical shifts ( $\delta$ ) were reported in parts per million relative to residual chloroform (7.28 ppm for  $^1\text{H}$ ; 77.23 ppm for  $^{13}\text{C}$ ), constants were reported in Hertz.  $^1\text{H}$  NMR assignment abbreviations were the following: singlet (s), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), doublet of triplets (dt), and multiplet (m).

UV/vis absorption spectra were recorded with a Jasco V-770 UV-Vis-NIR spectrophotometer using quartz cuvettes of 1 cm pathlength.

Steady-state luminescence spectra were measured using an Edinburgh FS920 Steady State Fluorimeter combined with a FL920 Fluorescence Lifetime Spectrometer. The spectra were corrected for the wavelength dependence of the detector, and the quoted emission maxima refer to the values after correction. Luminescence quantum yields were determined using  $[\text{Ru}(\text{bpy})_3]\text{Cl}_2$  ( $\Phi = 0.042$  in air-equilibrated aqueous solution)<sup>1</sup> as standard and correcting for the refractive index. Life-times measurements were conducted with 375 nm diode laser excitation (EPL-series) plugged to a TCSPC pulsed source interface.

Electronic circular dichroism spectra (ECD, in  $\text{M}^{-1}\cdot\text{cm}^{-1}$ ) were recorded on a Jasco J-815 Circular Dichroism Spectrometer (IFR140 facility - Biosit - Université de Rennes 1). Molar rotations are given in  $\text{deg}\cdot\text{cm}^2\cdot\text{mol}^{-1}$ .

Circularly polarized luminescence (CPL) measurements were performed using an in-house-developed CPL spectrofluoropolarimeter based on a Jasco J-701. The samples were excited using a 90°-geometry with a green InGaN (3 mm, 2 V) LED source (Luckylight Electronics Co., LTD,  $\lambda_{\text{max}} = 517$  nm, HWHM = 15 nm). The concentration of all the samples was  $\approx 10^{-5}$  M.

GC-MS analyses were performed with a GCMS-QP2010S (Shimadzu) instrument with a GC-2010 equipped with a 30 m capillary column (Supelco, SLBTM- 5ms, fused silica capillary column, 30 m x 0.25 mm x 0.25 mm film thickness), which was used with helium as the vector

gas. The following GC conditions were used: initial temperature 80 °C for 5 minutes, then rate 20 °C/min until 280 °C and 280 °C for 28 minutes.


HRMS were recorded on a Waters Q-ToF 2 or Bruker Ultraflex III mass spectrometers at the corresponding facilities of the CRMPO (Centre Régional de Mesures Physiques de l'Ouest, Université de Rennes 1).

Elemental Analysis were recorded on a Thermo Fisher FLASH 1112 at the corresponding facilities of the CRMPO

*fac*-[Ir(ppy)<sub>3</sub>] was prepared according to literature procedure.<sup>2</sup>

## **2. Procedure for the synthesis of NHPI redox-active esters & product characterizations**


According to literature reports,<sup>3</sup> the redox active esters can be synthesized by condensation of corresponding carboxylic acids with N-hydroxyphthalimide.



Scheme S1. Synthesis of Redox Active Esters

**General Procedure A:** The corresponding alkyl carboxylic acid (12 mmol, 1.2 equiv.), N-hydroxyphthalimide (1.63 g, 10 mmol, 1.0 equiv.), and 4-dimethylaminopyridine (61mg, 0.5 mmol, 5 mol %) were mixed in a flask with a magnetic stirring bar. Dry THF (40 mL) was added. Then a solution of N,N'-dicyclohexylcarbodiimide (2.48 g, 12 mmol, 1.2 equiv.) in THF (15 mL) was added slowly at room temperature. The reaction mixture was stirred at room temperature for 24 h. After N-hydroxyphthalimide was completely converted, the white precipitate was filtered off and the solution was concentrated under vacuum. Corresponding redox active esters were purified by column chromatography on silica gel (petroleum ether/ethyl acetate as eluent).

**1,3-Dioxoisindolin-2-yl cyclohexanecarboxylate (B1):** Following the general procedure **A**




using cyclohexanecarboxylic acid (1.53 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 95-5) to afford the desired compound **B1** (3.2 g, 85%) as a white solid.

$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.90 (dd,  $J = 5.5, 3.1$  Hz, 2H), 7.80 (dd,  $J = 5.5, 3.1$  Hz, 2H), 2.76 (tt,  $J = 10.9, 3.7$  Hz, 1H), 2.17 – 2.06 (m, 2H), 1.92 – 1.76 (m, 2H), 1.75 – 1.59 (m, 3H), 1.51 – 1.26 (m, 3H).

$^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  171.8, 162.0, 134.6, 129.0, 123.8, 40.4, 28.8, 25.4, 25.0.

The NMR data are identical to those reported in the literature.<sup>4</sup>

**1,3-Dioxoisindolin-2-yl cyclopentanecarboxylate (B2):** Following the general procedure **A**




using cyclopentanecarboxylic acid (1.4 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 95-5) to afford the desired compound **B2** (2.0 g, 78%) as a white solid.

$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.86 – 7.82 (m, 2H), 7.78 – 7.75 (m, 2H), 3.09 (quint.,  $J = 7.9$  Hz, 1H), 2.07 – 1.99 (m, 4H), 1.81 – 1.72 (m, 2H), 1.69 – 1.63 (m, 2H).

$^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  172.8, 162.0, 134.7, 128.9, 123.8, 40.6, 30.1, 25.9.

The NMR data are identical to those reported in the literature.<sup>4</sup>

**1,3-Dioxoisindolin-2-yl adamantane-1-carboxylate (B3):** Following the general **A**




procedure using 1-adamantanecarboxylic acid (2.16 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 95-5) to afford the desired compound **B3** (2.40 g, 74%) as a white solid.

$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.83 – 7.80 (m, 2H), 7.76 – 7.73 (m, 2H), 2.17 – 2.03 (m, 9H), 1.76 – 1.75 (m, 6H).

$^{13}\text{C NMR}$  (101 MHz,  $\text{CDCl}_3$ )  $\delta$  173.1, 162.0, 134.6, 129.0, 123.7, 40.4, 38.4, 36.1, 27.6.

The NMR data are identical to those reported in the literature.<sup>5</sup>

**1,3-Dioxoisindolin-2-yl tridecanoate (B4):** Following the general procedure **A** using




tridecanoic acid (2.56 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 95-5) to afford the desired compound **B4** (2.58 g, 72%) as a white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.87 – 7.84 (m, 2H), 7.78 – 7.75 (m, 2H), 2.65 (t, *J* = 7.4 Hz, 2H), 1.77 (quint., *J* = 7.1 Hz, 2H), 1.42 (q, *J* = 6.5 Hz, 2H), 1.30 – 1.25 (m, 16H), 0.87 (t, *J* = 6.4 Hz, 3H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 169.5, 161.9, 134.6, 128.9, 123.8, 31.9, 30.9, 29.6, 29.5, 29.3, 29.3, 29.1, 28.8, 24.6, 22.6, 14.0.

The NMR data are identical to those reported in the literature.<sup>6</sup>

**1,3-Dioxoisindolin-2-yl undec-10-enoate (B5):** Following the general **A** procedure using




undec-10-enoic acid (2.11 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 95-5) to afford the desired compound **B5** (2.57g, 79%) as a white oil.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.86 – 7.83 (m, 2H), 7.78 – 7.74 (m, 2H), 5.85 – 5.72 (m, 1H), 5.07 – 4.84 (m, 2H), 2.65 (t, *J* = 7.4 Hz, 2H), 2.03 (q, *J* = 6.6 Hz, 2H), 1.77 (quint., *J* = 7.3 Hz, 2H), 1.50 – 1.20 (m, 10H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 169.5, 161.9, 139.0, 134.7, 128.9, 123.8, 114.1, 33.7, 30.9, 29.1, 29.0, 28.9, 28.8, 28.7, 24.6.

The NMR data are identical to those reported in the literature.<sup>7</sup>

**1,3-Dioxoisindolin-2-yl methyl adipate (B6):** Following the general **A** procedure using




mono-methyl adipate (1.92 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 95-5) to afford the desired compound **B6** (2.16g, 71%) as a white oil.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.73 – 7.70 (m, 2H), 7.67 – 7.64 (m, 2H), 3.53 (s, 3H), 2.57 (t, *J* = 7.0 Hz, 2H), 2.25 (t, *J* = 6.9 Hz, 2H), 1.77 – 1.51 (m, 4H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 173.2, 169.1, 161.7, 134.7, 128.6, 123.7, 51.3, 33.2, 30.4, 23.9, 23.8.

**HRMS (ESI)** Calcd for: C<sub>15</sub>H<sub>16</sub>NO<sub>6</sub>: 306.0972; Found: 306.0974 [M+H]<sup>+</sup>.

**1,3-Dioxoisindolin-2-yl 1-tosylpiperidine-4-carboxylate (B7):** To a solution of piperidine-



4- carboxylic acid (2.6 g, 20.0 mmol) in diethyl ether (20 mL) and water (20 mL) in a 100-mL round-bottom flask was added NaOH (1.6 g, 40.0 mmol). To the vigorously stirring solution was added TsCl (3.82 g, 20.0 mmol) portionwise over 15 min. The reaction


was stirred at ambient temperature for 6 h, and then was diluted with equal portions of diethyl ether and water until all precipitates were redissolved. The aqueous layer was collected and acidified to pH = 2–3 with dropwise addition of 6N HCl. The precipitate was collected by filtration and used without further purification in the next step. Following the general **A** procedure using 1-tosylpiperidine-4-carboxylic acid (3.4 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 80-2) to afford the desired compound **B7** (3.28 g, 64%) as a white oil.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.88 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.83 – 7.75 (m, 2H), 7.67 (d, *J* = 8.3 Hz, 2H), 7.35 (d, *J* = 8.3 Hz, 2H), 3.73 – 3.56 (m, 2H), 2.80 – 2.71 (m, 1H), 2.67 (ddd, *J* = 12.4, 10.2, 3.1 Hz, 2H), 2.45 (s, 3H), 2.23 – 2.13 (m, 2H), 2.11 – 1.98 (m, 2H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 170.2, 161.8, 143.8, 134.9, 133.2, 129.8, 128.8, 127.6, 124.0, 123.9, 44.9, 37.5, 27.3, 21.5.

The NMR data are identical to those reported in the literature.<sup>3c</sup>

**1,3-Dioxoisindolin-2-yl dehydrocholate (B8):** Following the general procedure using




dehydrocholic acid (4.83 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 40-60) to afford the desired compound **B8** (3.17 g, 58%) as a white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.90 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.81 (dd, *J* = 5.5, 3.1 Hz, 2H), 3.00 – 2.84 (m, 3H), 2.82 – 2.74 (m, 1H), 2.70 – 2.62 (m, 1H), 2.44 – 2.14 (m, 8H), 2.05 – 1.82 (m, 4H), 1.78 – 1.51 (m, 4H), 1.42 (s, 3H), 1.36 – 1.21 (m, 3H), 1.14 (s, 3H), 0.94 (d, *J* = 6.5 Hz, 3H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 211.8, 209.0, 208.6, 169.8, 161.9, 134.7, 128.9, 123.9, 56.9, 51.7, 49.0, 46.8, 45.6, 45.5, 44.9, 42.8, 38.6, 36.5, 36.0, 35.2, 33.9, 30.3, 28.5, 27.6, 25.6, 25.1, 24.9, 21.9, 18.5, 11.8.

The NMR data are identical to those reported in the literature.<sup>8</sup>

**(-) 1,3-Dioxoisindolin-2-yl menthyloxyacetate ((-)B9):** Following the general procedure



using (-)-menthyloxyacetic acid (2.57 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 40-60) to afford the desired compound **(-)B8** (3.19 g, 89%) as a white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.89 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.80 (dd, *J* = 5.5, 3.1 Hz, 2H), 4.53 (s, 2H), 3.30 (td, *J* = 10.6, 4.2 Hz, 1H), 2.38 – 2.23 (m, 1H), 2.15 (dtd, *J* = 12.1, 3.8, 1.8 Hz, 1H), 1.71 –


1.61 (m, 2H), 1.46 – 1.26 (m, 2H), 1.07 – 0.98 (m, 1H), 0.95 (d,  $J = 7.4$  Hz, 3H), 0.91 (d,  $J = 7.1$  Hz, 3H), 0.90 – 0.84 (m, 2H), 0.80 (d,  $J = 6.9$  Hz, 3H).

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  167.3, 161.7, 134.8, 128.9, 124.0, 80.8, 63.5, 48.2, 39.8, 34.3, 31.4, 25.4, 23.2, 22.2, 21.0, 16.2.

HRMS (ESI) Calcd for:  $\text{C}_{20}\text{H}_{26}\text{NO}_5$ : 360.1805; Found: 360.1806  $[\text{M}+\text{H}]^+$ .

$[\alpha]_{\text{D}}^{25} = -75.2$  ( $c = 0.002$  in  $\text{CH}_2\text{Cl}_2$ )

**(+) 1,3-Dioxoisindolin-2-yl menthyloxyacetate ((+)B9):** Following the general procedure



using (+)-menthyloxyacetic acid (2.57 g, 12 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 40-60) to afford the desired compound **(+)B8** (3.05 g, 85%) as a white solid.

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.89 (dd,  $J = 5.5, 3.1$  Hz, 2H), 7.80 (dd,  $J = 5.5, 3.1$  Hz, 2H), 4.53 (s, 2H), 3.30 (td,  $J = 10.6, 4.2$  Hz, 1H), 2.38 – 2.23 (m, 1H), 2.15 (dtd,  $J = 12.1, 3.8, 1.8$  Hz, 1H), 1.71 – 1.61 (m, 2H), 1.46 – 1.26 (m, 2H), 1.07 – 0.98 (m, 1H), 0.95 (d,  $J = 7.4$  Hz, 3H), 0.91 (d,  $J = 7.1$  Hz, 3H), 0.90 – 0.84 (m, 2H), 0.80 (d,  $J = 6.9$  Hz, 3H).

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  167.3, 161.7, 134.8, 128.9, 124.0, 80.8, 63.5, 48.2, 39.8, 34.3, 31.4, 25.4, 23.2, 22.2, 21.0, 16.2.


HRMS (ESI) Calcd for:  $\text{C}_{20}\text{H}_{26}\text{NO}_5$ : 360.1805; Found: 360.1806  $[\text{M}+\text{H}]^+$ .

$[\alpha]_{\text{D}}^{25} = 75.2$  ( $c = 0.02$  in  $\text{CH}_2\text{Cl}_2$ )

### 3. Procedure for Photo Photoredox-catalyzed Minisci-type alkylation of 6-aryl-2,2'-bipyridines & product characterizations

**General Procedure B:** To a 15 mL oven-dried Schlenk tube, *fac*-[Ir(ppy)<sub>3</sub>] (4.08 mg, 0.0125 mmol, 2.5 mol%), bipyridine (0.5 mmol), NHPI redox-active esters (2 equiv., 1 mmol), DMS (1.6 mL), and TFA (0.4 mL) were successfully added under an argon atmosphere. The Schlenk was positioned on a stir plate approximately 2–3 cm from two ABI PAR38 (24 W) LED lamps supplying blue light ( $\lambda = 440\text{--}460$  nm). Fans were used for cooling. After irradiation for 72 h, the reaction mixture was poured into a saturated aqueous solution of  $\text{K}_2\text{CO}_3$  (10 mL) and extracted several times with AcOEt (4 × 15 mL). The solvent was removed under reduced pressure, and the residue was purified by flash chromatography (petroleum ether/ethyl acetate) to produce the desired product.

**4,4'-Di-*tert*-butyl-6-cyclohexyl-6'-phenyl-2,2'-bipyridine (C1):** Following the general procedure **B** using 4,4'-di-*tert*-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl cyclohexanecarboxylate (**B1**) (273 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 90-10) to afford the desired compound **C1** (143 mg, 67%) as a white solid.




**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.58 (s, 1H), 8.53 (s, 1H), 8.26 (d, *J* = 7.5 Hz, 2H), 7.85 (s, 1H), 7.60 (t, *J* = 7.5 Hz, 2H), 7.51 (t, *J* = 7.2 Hz, 1H), 7.27 (s, 1H), 2.91 (tt, *J* = 11.8, 3.4 Hz, 1H), 2.23 – 2.10 (m, 2H), 2.03 – 1.98 (m, 2H), 1.90 – 1.86 (m, 1H), 1.82 – 1.70 (m, 2H), 1.66 – 1.56 (m, 2H), 1.55 (s, 9H), 1.50 (s, 9H), 1.50 – 1.43 (m, 1H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 165.6, 161.3, 160.8, 157.0, 156.3, 155.8, 140.3, 128.7, 127.1, 117.8, 117.2, 117.0, 115.9, 46.7, 35.2, 35.0, 33.2, 30.8, 30.8, 26.8, 26.3.

**HRMS (ESI)** Calcd for: C<sub>30</sub>H<sub>38</sub>N<sub>2</sub>Na: 449.2927; Found: 449.2927 [M+Na]<sup>+</sup>.

**4,4'-Di-*tert*-butyl-6-cyclopentyl-6'-phenyl-2,2'-bipyridine (C2):** Following the general procedure **B** using 4,4'-di-*tert*-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl cyclopentanecarboxylate (**B2**) (259 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 90-10) to afford the desired compound **C2** (128 mg, 62%) as a white solid.




**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.64 (s, 1H), 8.57 (s, 1H), 8.29 (d, *J* = 7.3 Hz, 2H), 7.87 (s, 1H), 7.62 (t, *J* = 7.5 Hz, 2H), 7.53 (t, *J* = 7.3 Hz, 2H), 7.30 (s, 1H), 3.42 (quint., *J* = 7.7 Hz, 2H), 2.37 – 2.18 (m, 2H), 2.15 – 1.94 (m, 4H), 1.93 – 1.78 (m, 2H), 1.56 (s, 9H), 1.52 (s, 9H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 165.0, 161.3, 160.7, 156.9, 156.4, 155.8, 140.3, 128.7, 127.1, 118.6, 117.2, 117.0, 115.6, 48.0, 35.2, 34.9, 33.8, 30.8, 30.8, 26.1.

**HRMS (ESI)** Calcd for: C<sub>29</sub>H<sub>36</sub>N<sub>2</sub>Na: 435.2770; Found: 435.2772 [M+Na]<sup>+</sup>.

**4,4'-Di-*tert*-butyl-6-adamantyl-6'-phenyl-2,2'-bipyridine (B3):** Following the general procedure **B** using 4,4'-di-*tert*-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl adamantane-1-carboxylate (**B3**) (325 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 90-10) to afford the desired compound **B3** (206 mg, 86%) as a white solid.






**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.69 (s, 1H), 8.57 (s, 1H), 8.28 (d, *J* = 7.5 Hz, 2H), 7.86 (s, 1H), 7.62 (t, *J* = 7.4 Hz, 2H), 7.53 (t, *J* = 7.0 Hz, 1H), 7.42 (s, 1H), 2.28 – 2.22 (m, 10H), 1.96 – 1.95 (m, 5H), 1.57 (s, 9H), 1.53 (s, 9H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 168.1, 161.2, 160.6, 157.2, 156.3, 155.1, 140.4, 128.7, 128.7, 127.1, 117.1, 117.0, 115.5, 115.3, 42.3, 39.4, 37.1, 35.2, 30.9, 30.8, 29.1.

**HRMS (ESI)** Calcd for: C<sub>34</sub>H<sub>42</sub>N<sub>2</sub>Na: 501.3240; Found: 501.3240 [M+Na]<sup>+</sup>.

**4,4'-di-*tert*-butyl-6-dodecyl-6'-phenyl-2,2'-bipyridine (C4):** Following the general procedure




**B** using 4,4'-di-*tert*-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl tridecanoate (**B4**) (359 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 90-10) to afford the desired compound **C4** (241 mg, 47%) as a white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.52 (s, 1H), 8.49 (s, 1H), 8.23 (d, *J* = 7.2 Hz, 2H), 7.82 (s, 1H), 7.57 (t, *J* = 7.5 Hz, 2H), 7.48 (t, *J* = 7.3 Hz, 2H), 7.22 (s, 1H), 2.95 (t, *J* = 7.6 Hz, 2H), 1.92 (p, *J* = 7.6 Hz, 2H), 1.52 (s, 9H), 1.47 (s, 9H), 1.37 – 1.34 (m, 17H), 1.05 – 0.84 (m, 4H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 161.6, 161.3, 160.7, 156.8, 156.3, 156.0, 140.2, 128.6, 128.6, 127.1, 119.5, 117.2, 116.9, 115.7, 38.5, 35.1, 34.9, 31.9, 30.7, 29.8, 29.7, 29.7, 29.6, 29.5, 29.4, 22.7, 14.1.

**HRMS (ESI)** Calcd for: C<sub>36</sub>H<sub>52</sub>N<sub>2</sub>Na: 535.4023; Found: 535.4022 [M+Na]<sup>+</sup>.

**4,4'-Di-*tert*-butyl-6-(dec-9-en-1-yl)-6'-phenyl-2,2'-bipyridine (C5):** Following the general



procedure **B** using 4,4'-di-*tert*-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl undec-10-enoate (**B5**) (329 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 90-10) to afford the desired compound **C5** (94


mg, 39%) as a white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.50 (s, 1H), 8.48 (s, 1H), 8.22 (d, *J* = 7.2 Hz, 2H), 7.81 (s, 1H), 7.57 (t, *J* = 7.5 Hz, 2H), 7.48 (t, *J* = 7.3 Hz, 1H), 7.21 (s, 1H), 5.92 – 5.82 (m, 1H), 5.11 – 4.93 (m, 2H), 2.94 (t, *J* = 6.8 Hz, 2H), 2.10 (q, *J* = 6.8 Hz, 2H), 1.91 (quint., *J* = 7.6 Hz, 2H), 1.51 (s, 9H), 1.46 (s, 9H), 1.44 – 1.33 (m, 10H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 161.6, 161.3, 160.7, 156.8, 156.3, 156.0, 140.2, 139.2, 128.6, 128.6, 127.1, 119.5, 117.2, 116.9, 115.7, 114.1, 38.5, 35.1, 34.9, 33.8, 30.7, 29.7, 29.5, 29.5, 29.5, 29.2, 29.0.

**HRMS (ESI)** Calcd for: C<sub>34</sub>H<sub>46</sub>N<sub>2</sub>Na: 505.3553; Found: 505.3550 [M+Na]<sup>+</sup>.

**Methyl 5-(4,4'-di-*tert*-butyl-6'-phenyl-[2,2'-bipyridin]-6-yl)pentanoate (C6):** Following the general procedure **B** using 4,4'-di-*tert*-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl methyl adipate (**B6**) (305 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 80-20) to afford the desired compound **C6** (133 mg, 58%) as a white solid.




**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.45 (s, 2H), 8.18 (d, *J* = 7.2 Hz, 2H), 7.78 (s, 1H), 7.55 (t, *J* = 7.5 Hz, 2H), 7.46 (t, *J* = 7.3 Hz, 1H), 7.18 (s, 1H), 3.70 (s, 3H), 2.93 (t, *J* = 7.5 Hz, 2H), 2.45 (t, *J* = 7.4 Hz, 2H), 1.98 – 1.88 (m, 2H), 1.88 – 1.77 (m, 2H), 1.48 (s, 9H), 1.43 (s, 9H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 174.1, 161.4, 160.9, 160.8, 156.6, 156.3, 156.1, 140.1, 128.6, 128.6, 127.0, 119.5, 117.3, 116.8, 115.9, 51.4, 37.9, 35.1, 34.9, 34.0, 30.7, 30.7, 29.1, 24.7.

**HRMS (ESI)** Calcd for: C<sub>30</sub>H<sub>38</sub>N<sub>2</sub>O<sub>2</sub>Na: 481.2825; Found: 481.2827 [M+Na]<sup>+</sup>.

**4,4'-Di-*tert*-butyl-6-phenyl-6'-(1-tosylpiperidin-4-yl)-2,2'-bipyridine (C7):** Following the general procedure **B** using 4,4'-di-*tert*-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl 1-tosylpiperidine-4-carboxylate (**B7**) (428 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 80-20) to afford the desired compound **C7** (212 mg, 73%) as a white solid.




**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.49 (d, *J* = 1.8 Hz, 1H), 8.44 (d, *J* = 1.7 Hz, 1H), 8.27 – 8.08 (m, 2H), 7.78 (d, *J* = 1.7 Hz, 1H), 7.74 (d, *J* = 8.2 Hz, 2H), 7.54 (t, *J* = 7.5 Hz, 2H), 7.49 – 7.43 (m, 1H), 7.38 (d, *J* = 8.0 Hz, 2H), 7.12 (d, *J* = 1.8 Hz, 1H), 4.01 (dd, *J* = 9.9, 5.1 Hz, 2H), 2.74 (d, *J* = 7.8 Hz, 1H), 2.46 (d, *J* = 10.8 Hz, 5H), 2.11 (dt, *J* = 7.9, 4.7 Hz, 4H), 1.47 (s, 9H), 1.41 (s, 9H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 162.7, 161.5, 161.3, 156.4, 156.0, 143.5, 140.1, 133.2, 129.6, 128.7, 128.7, 127.8, 127.7, 127.1, 117.8, 117.4, 116.8, 116.4, 46.7, 43.7, 35.2, 35.0, 31.3, 30.8, 30.7, 21.6.

**HRMS (ESI)** Calcd for: C<sub>36</sub>H<sub>43</sub>N<sub>3</sub>O<sub>2</sub>SNa 627.2866; Found: 627.2865 [M+Na]<sup>+</sup>.

**(8*S*,9*R*,10*R*,13*S*,14*R*,17*S*)-17-((*R*)-4-(4,4'-Di-*tert*-butyl-6'-phenyl-[2,2'-bipyridin]-6-yl)butan-2-yl)-10,13-dimethyldodecahydro-3*H*-cyclopenta[*a*]phenanthrene-3,7,12(2*H*,4*H*)-trione (C8):** Following the general procedure **B** using 4'-di-*tert*-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl dehydrocholate (**B8**) (547 mg, 1 mmol, 2 equiv.), the residue was purified by flash



chromatography on silica gel (heptane-EtOAc, 40-60) to afford the desired compound **C8** (165 mg, 47%) as a white solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.46 (s, 1H), 8.42 (s, 1H), 8.16 (d, *J* = 7.2 Hz, 2H), 7.76 (s, 1H), 7.52 (t, *J* = 7.5 Hz, 2H), 7.44 (t, *J* = 7.3 Hz, 1H), 7.16 (s, 1H), 3.05 – 2.75 (m, 5H), 2.41 – 2.09 (m, 6H), 2.06 – 1.81 (m, 9H), 1.63 (tdd, *J* = 13.8, 10.1, 4.1 Hz, 2H), 1.45 (s, 9H), 1.43 – 1.36 (m, 10H), 1.09 – 1.05 (m, 4H), 1.03 – 1.00 (m, 3H), 0.91 – 0.82 (m, 3H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 212.1, 209.1, 208.8, 161.6, 161.4, 160.8, 156.7, 156.3, 155.9, 140.1, 128.7, 128.6, 127.0, 119.6, 117.3, 116.9, 115.6, 57.0, 51.8, 49.0, 46.8, 46.0, 45.6, 45.0, 42.8, 38.7, 37.4, 36.5, 36.0, 35.7, 35.3, 34.9, 33.9, 30.7, 27.9, 25.6, 25.2, 25.0, 21.9, 19.0, 18.5, 11.9, 10.9.

**HRMS (ESI)** Calcd for: C<sub>47</sub>H<sub>60</sub>N<sub>2</sub>O<sub>3</sub>Na: 723.4496; Found: 723.4495 [M+Na]<sup>+</sup>.

[α]<sub>D</sub><sup>25</sup> = -134.4 (c = 0.02 in CH<sub>2</sub>Cl<sub>2</sub>)

**4,4'-Di-tert-butyl-6-((((1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-**



**bipyridine ((-)**C9**):** Following the general procedure **B** using 4'-di-tert-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and (-) 1,3-dioxoisindolin-2-yl menthyloxyacetate ((-)**B9**) (359 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 40-60) to afford the desired compound ((-)**C9**) (171 mg, 67%) as a white solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.57 (d, *J* = 1.8 Hz, 1H), 8.47 (d, *J* = 1.7 Hz, 1H), 8.20 (dt, *J* = 6.5, 1.3 Hz, 2H), 7.80 (d, *J* = 1.7 Hz, 1H), 7.58 (d, *J* = 1.8 Hz, 1H), 7.55 (dd, *J* = 8.4, 7.0 Hz, 2H), 7.49 – 7.42 (m, 1H), 4.94 (d, *J* = 12.9 Hz, 1H), 4.71 (d, *J* = 12.9 Hz, 1H), 3.40 – 3.25 (m, 2H), 2.50 – 2.38 (m, 1H), 2.37 – 2.26 (m, 1H), 2.27 – 2.12 (m, 1H), 1.81 – 1.59 (m, 5H), 1.49 (s, 3H), 1.46 (s, 3H), 1.34 – 1.22 (m, 4H), 1.11 – 1.03 (m, 4H), 1.02 – 0.98 (m, 5H), 0.98 – 0.88 (m, 8H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 161.5, 161.2, 158.7, 156.4, 155.8, 140.1, 128.7, 128.7, 127.1, 118.7, 117.4, 117.0, 116.9, 111.9, 95.3, 79.8, 72.0, 64.6, 48.3, 40.6, 35.2, 35.1, 34.7, 31.6, 30.8, 30.7, 26.0, 23.5, 22.4, 21.0, 16.4.

**HRMS (ESI)** Calcd for: C<sub>35</sub>H<sub>48</sub>N<sub>2</sub>O<sub>3</sub>Na: 535.3659; Found: 535.3658 [M+Na]<sup>+</sup>.

[α]<sub>D</sub><sup>25</sup> = -146.9 (c = 0.02 in CH<sub>2</sub>Cl<sub>2</sub>)

**4,4'-Di-tert-butyl-6-(((1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-**



**bipyridine ((+)C9):** Following the general procedure **B** using 4'-di-tert-butyl-6-phenyl-2,2'-bipyridine (172 mg, 0.5 mmol) and (-) 1,3-dioxoisindolin-2-yl menthylxyacetate ((+)B9) (359 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 40-60) to afford the desired compound (-)C9 (184 mg, 72%) as a white solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.57 (d, *J* = 1.8 Hz, 1H), 8.47 (d, *J* = 1.7 Hz, 1H), 8.20 (dt, *J* = 6.5, 1.3 Hz, 2H), 7.80 (d, *J* = 1.7 Hz, 1H), 7.58 (d, *J* = 1.8 Hz, 1H), 7.55 (dd, *J* = 8.4, 7.0 Hz, 2H), 7.49 – 7.42 (m, 1H), 4.94 (d, *J* = 12.9 Hz, 1H), 4.71 (d, *J* = 12.9 Hz, 1H), 3.40 – 3.25 (m, 2H), 2.50 – 2.38 (m, 1H), 2.37 – 2.26 (m, 1H), 2.27 – 2.12 (m, 1H), 1.81 – 1.59 (m, 5H), 1.49 (s, 3H), 1.46 (s, 3H), 1.34 – 1.22 (m, 4H), 1.11 – 1.03 (m, 4H), 1.02 – 0.98 (m, 5H), 0.98 – 0.88 (m, 8H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 161.5, 161.2, 158.7, 156.4, 155.8, 140.1, 128.7, 128.7, 127.1, 118.7, 117.4, 117.0, 116.9, 111.9, 95.3, 79.8, 72.0, 64.6, 48.3, 40.6, 35.2, 35.1, 34.7, 31.6, 30.8, 30.7, 26.0, 23.5, 22.4, 21.0, 16.4.

**HRMS (ESI)** Calcd for: C<sub>35</sub>H<sub>48</sub>N<sub>2</sub>ONa: 535.3659; Found: 535.3658 [M+Na]<sup>+</sup>.

[α]<sub>D</sub><sup>25</sup> = 146.9 (c = 0.002 in CH<sub>2</sub>Cl<sub>2</sub>)

**4,4'-Di-tert-butyl-6-adamantyl-6'-(4-bromophenyl)-2,2'-bipyridine (C10):** Following the




general procedure **B** using 6-(4-bromophenyl)-4,4'-di-tert-butyl-2,2'-bipyridine (211 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl adamantane-1-carboxylate (**B3**) (325 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 90-10) to afford the desired compound **B10** (201 mg, 71%) as a white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.58 (d, *J* = 1.7 Hz, 1H), 8.40 (d, *J* = 1.7 Hz, 1H), 8.10 – 7.99 (m, 2H), 7.72 (d, *J* = 1.7 Hz, 1H), 7.69 – 7.61 (m, 2H), 7.32 (d, *J* = 1.7 Hz, 1H), 2.22 – 2.16 (m, 3H), 2.17 – 2.11 (m, 6H), 1.90 – 1.82 (m, 6H), 1.47 (s, 9H), 1.43 (s, 9H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 168.1, 161.4, 160.7, 157.3, 155.1, 154.8, 139.2, 131.7, 128.7, 123.0, 117.3, 116.8, 115.7, 115.2, 42.2, 39.3, 37.0, 35.1, 35.1, 30.9, 30.7, 29.0.

**HRMS (ESI)** Calcd for: C<sub>34</sub>H<sub>41</sub>BrN<sub>2</sub>Na: 579.2345; Found: 579.2342 [M+Na]<sup>+</sup>.

**4,4'-Di-tert-butyl-6-adamantyl-6'-(4-chlorophenyl)-2,2'-bipyridine (C11):** Following the




general procedure **B** using 6-(4-chlorophenyl)-4,4'-di-tert-butyl-2,2'-bipyridine (189 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl adamantane-1-carboxylate (**B3**) (325 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 90-10) to afford the desired compound **C11** (189 mg, 74%) as a white solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$  8.57 (d,  $J$  = 1.7 Hz, 1H), 8.40 (d,  $J$  = 1.7 Hz, 1H), 8.16 – 8.06 (m, 2H), 7.71 (d,  $J$  = 1.7 Hz, 1H), 7.50 (d,  $J$  = 8.5 Hz, 2H), 7.32 (d,  $J$  = 1.7 Hz, 1H), 2.27 – 2.17 (m, 3H), 2.15 – 2.10 (m, 6H), 1.93 – 1.83 (m, 6H), 1.47 (s, 9H), 1.43 (s, 9H).  
**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$  168.1, 161.4, 160.7, 157.2, 155.1, 154.9, 138.7, 134.7, 128.8, 128.3, 117.2, 116.8, 115.6, 115.2, 42.2, 39.3, 37.0, 35.1, 35.1, 30.9, 30.7, 29.0.

**HRMS (ESI)** Calcd for: C<sub>34</sub>H<sub>41</sub>ClN<sub>2</sub>Na: 535.2850; Found: 535.2850 [M+Na]<sup>+</sup>.

**4,4'-Dimethyl-6-adamantyl-6'-(4-bromophenyl)-2,2'-bipyridine (C12):** Following the



general procedure **B** using 6-(4-bromophenyl)-4,4'-dimethyl-2,2'-bipyridine (169 mg, 0.5 mmol) and 1,3-dioxoisindolin-2-yl adamantane-1-carboxylate (**B3**) (325 mg, 1 mmol, 2 equiv.), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 90-10) to afford the desired compound **C12** (158 mg, 67%) as a white solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$  8.33 (s, 1H), 8.21 (s, 1H), 8.04 (d,  $J$  = 8.6 Hz, 2H), 7.64 (d,  $J$  = 8.5 Hz, 2H), 7.55 (s, 1H), 7.14 (s, 1H), 2.54 (s, 3H), 2.47 (s, 3H), 2.21 – 2.15 (m, 3H), 2.13 – 2.09 (m, 6H), 1.89 – 1.80 (m, 6H).  
**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$  168.2, 156.8, 155.1, 154.6, 148.6, 147.7, 138.7, 131.7, 128.6, 123.1, 120.8, 120.7, 119.9, 119.0, 42.1, 39.0, 37.0, 29.7, 28.9, 21.6, 21.5.

**HRMS (ESI)** Calcd for: C<sub>28</sub>H<sub>29</sub>BrN<sub>2</sub>Na: 495.1406; Found: 495.1403 [M+Na]<sup>+</sup>.

**4. Procedure for the preparation of cyclometalated Pt(II) chloride complexes & product characterizations**

**General Procedure C:** A mixture of 6'-alkyl-4,4'-di-tert-butyl-6-phenyl-2,2'-bipyridine pro-ligands (0.25 mmol) and K<sub>2</sub>PtCl<sub>4</sub> (62 mg, 0.15 mmol) in CH<sub>3</sub>CO<sub>2</sub>H (15 mL) was refluxed for 48 h. The red solution was evaporated to dryness and was purified by flash chromatography on silica gel (heptane-EtOAc) to afford the desired compound.

**Chloro(*N,N,6C'*)-4,4'-di-*tert*-butyl-6-cyclohexyl-6'-phenyl-2,2'-bipyridine platinum (D1):**




Following the general procedure **C** using 4,4'-di-*tert*-butyl-6-cyclohexyl-6'-phenyl-2,2'-bipyridine (**C1**) (64.0 mg, 0.15 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 80-20) to afford the desired compound **D1** (83.6 mg, 85%) as a yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.02 (d, *J* = 8.6 Hz, 1H), 7.75 (s, 1H), 7.59 (s, 1H), 7.56 (s, 1H), 7.54 (s, 1H), 7.37 (d, *J* = 7.7 Hz, 1H), 7.24 (t, *J* = 7.5 Hz, 1H), 7.08 (t, *J* = 7.5 Hz, 1H), 4.66 (tt, *J* = 11.9, 3.2 Hz, 1H), 2.23 – 2.05 (m, 2H), 1.83 (dt, *J* = 15.3, 10.7 Hz, 5H), 1.47 (s, 9H), 1.45 (s, 9H), 1.39 – 1.26 (m, 3H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)** δ 172.8, 165.4, 163.2, 162.6, 156.6, 155.3, 145.7, 136.4, 133.8, 130.3, 123.9, 123.4, 121.7, 116.6, 115.1, 114.7, 43.5, 35.8, 35.4, 34.1, 30.3, 26.2, 25.5.

**Elemental Analysis:** calcd for: C<sub>30</sub>H<sub>37</sub>ClN<sub>2</sub>Pt: C, 54.91. H, 5.68, N, 4.27. Found: C, 54.86. H, 5.67. N, 4.12.

**Chloro(*N,N,6C'*)-4,4'-di-*tert*-butyl-6-cyclopentyl-6'-phenyl-2,2'-bipyridine platinum (D2):**




Following the general procedure **C** using 4,4'-di-*tert*-butyl-6-cyclopentyl-6'-phenyl-2,2'-bipyridine (**C2**) (61.9 mg, 0.15 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 80-20) to afford the desired compound **D2** (81.9 mg, 85%) as a yellow solid.

**<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>)** δ 8.32 (s, 1H), 8.16 (s, 1H), 7.90 (d, *J* = 7.8 Hz, 1H), 7.86 (s, 1H), 7.78 (s, 1H), 7.55 (d, *J* = 8.7 Hz, 1H), 7.11 (t, *J* = 7.5 Hz, 1H), 6.99 (t, *J* = 7.5 Hz, 1H), 5.10 – 4.98 (m, 1H), 2.40 – 2.24 (m, 2H), 1.90 – 1.76 (m, 4H), 1.73 – 1.63 (m, 2H), 1.50 (s, 9H), 1.47 (s, 9H).

**<sup>13</sup>C NMR (101 MHz, Acetone-*d*<sub>6</sub>)** δ 171.5, 164.9, 164.0, 163.4, 156.5, 155.3, 146.4, 137.2, 133.5, 129.2, 123.8, 123.4, 121.7, 118.2, 116.5, 115.6, 46.6, 35.9, 35.3, 34.5, 29.5, 29.5, 25.4.

**Elemental Analysis:** calcd for: C<sub>29</sub>H<sub>35</sub>ClN<sub>2</sub>Pt: C, 54.24. H, 5.49, N, 4.36. Found: C, 54.08. H, 5.31. N, 4.49.

**Chloro(*N,N,6C'*)-4,4'-di-*tert*-butyl-6-adamantyl-6'-phenyl-2,2'-bipyridine platinum (D3):**



Following the general procedure **C** using 4,4'-di-*tert*-butyl-6-adamantyl-6'-phenyl-2,2'-bipyridine (**C3**) (71.8 mg, 0.15 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 80-20) to afford the desired compound **D3** (37.2 mg, 35%) as a yellow solid.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.99 (d, *J* = 7.8 Hz, 1H), 7.84 (s, 1H), 7.69 (s, 1H), 7.52 (s, 1H), 7.50 (s, 1H), 7.37 (d, *J* = 7.4 Hz, 1H), 7.15 (t, *J* = 6.9 Hz,

1H), 7.06 (t,  $J = 7.4$  Hz, 1H), 2.17 – 2.16 (m, 7H), 2.06 – 2.03 (m, 4H), 1.74 – 1.71 (m, 4H), 1.45 (s, 9H), 1.43 (s, 9H).

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  177.2, 164.3, 163.2, 162.9, 156.5, 155.4, 144.8, 134.4, 131.5, 129.9, 123.9, 123.4, 122.0, 116.1, 115.8, 115.0, 41.4, 40.6, 36.3, 35.8, 35.3, 30.9, 30.4, 29.0.

**Elemental Analysis:** calcd for:  $\text{C}_{34}\text{H}_{41}\text{ClN}_2\text{Pt}$ : C, 57.66. H, 5.84, N, 3.96. Found: C, 57.89. H, 5.98. N, 4.09.

#### Chloro(*N,N,6C'*)-4,4'-Di-*tert*-butyl-6-dodecyl-6'-phenyl-2,2'-bipyridine platinum (D4):




Following the general procedure **C** using 4,4'-di-*tert*-butyl-6-dodecyl-6'-phenyl-2,2'-bipyridine (**C4**) (76.9 mg, 0.15 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 80-20) to afford the desired compound **D4** (63.5 mg, 57%) as a yellow solid.

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.94 (d,  $J = 7.6$  Hz, 1H), 7.72 (s, 1H), 7.53 (s, 1H), 7.50 (s, 1H), 7.41 (s, 1H), 7.32 (d,  $J = 7.0$  Hz, 1H), 7.19 (t,  $J = 8.0$  Hz, 1H), 7.04 (t,  $J = 7.4$  Hz, 1H), 3.53 (t,  $J = 7.8$  Hz, 3H), 1.78 (quint.,  $J = 7.8$  Hz, 2H), 1.46 (s, 9H), 1.44 (s, 9H), 1.26 (m, 18H), 0.89 (t,  $J = 6.8$  Hz, 5H).

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  168.7, 165.4, 162.9, 162.6, 157.1, 155.1, 145.8, 136.9, 133.8, 130.2, 125.3, 123.7, 123.4, 116.5, 115.1, 114.8, 38.5, 35.8, 35.2, 31.9, 31.7, 30.4, 30.3, 29.7, 29.6, 29.3, 29.1, 22.6, 14.1.

**Elemental Analysis:** calcd for:  $\text{C}_{36}\text{H}_{51}\text{ClN}_2\text{Pt}$ : C, 58.25. H, 6.93, N, 4.78. Found: C, 58.44. H, 7.12. N, 4.53.

#### Mixture of isomers chloro(*N,N,6C'*)-4,4'-Di-*tert*-butyl-6-decenyl-6'-phenyl-2,2'-bipyridine platinum (D5):




Following the general procedure **C** using 4,4'-di-*tert*-butyl-6-(dec-9-en-1-yl)-6'-phenyl-2,2'-bipyridine (**C5**) (72.4 mg, 0.15 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 80-20) to afford the desired compound **D5** (50.1 mg, 47%) as a yellow solid.

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.97 (dd,  $J = 7.8, 1.2$  Hz, 1H), 7.74 (d,  $J = 2.0$  Hz, 1H), 7.54 (dd,  $J = 10.1, 1.7$  Hz, 2H), 7.43 (d,  $J = 2.0$  Hz, 1H), 7.35 (dd,  $J = 7.7, 1.4$  Hz, 1H), 7.22 (td,  $J = 7.5, 1.5$  Hz, 1H), 7.07 (td,  $J = 7.5, 1.3$  Hz, 1H), 5.82 (ddt,  $J = 16.9, 10.2, 6.7$  Hz, 0.2H), 5.48 – 5.32 (m, 1.4H), 4.99 (dq,  $J = 17.2, 1.7$  Hz, 0.2H), 4.93 (ddt,  $J = 10.2, 2.4, 1.3$  Hz, 0.2H), 3.62 – 3.51 (m, 2H), 2.08 – 1.91 (m, 2H), 1.85 – 1.73 (m, 2H), 1.68 – 1.57 (m, 3H), 1.46 (s, 9H), 1.44 (s, 9H), 1.40 – 1.24 (m, 8H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ** 168.8, 165.5, 163.1, 162.7, 157.2, 155.2, 145.9, 139.3, 136.9, 133.9, 131.8, 131.8, 131.0, 130.4, 129.4, 125.4, 124.5, 123.9, 123.5, 123.5, 116.5, 115.2, 114.9, 114.8, 114.0, 38.5, 35.8, 35.2, 33.8, 32.6, 30.4, 30.3, 29.6, 29.6, 29.6, 29.5, 29.5, 29.5, 29.2, 29.2, 29.1, 29.1, 28.9.

**Elemental Analysis:** calcd for: C<sub>34</sub>H<sub>45</sub>ClN<sub>2</sub>Pt: C, 57.33. H, 6.37, N, 3.93. Found: C, 57.21. H, 6.24. N, 3.87.

**Methyl chloro(*N,N,6C''*)-5-(4,4'-di-*tert*-butyl-6'-phenyl-[2,2'-bipyridin]-6-yl)pentanoate platinum (D6):**




Following the general procedure **C** using methyl 5-(4,4'-di-*tert*-butyl-6'-phenyl-[2,2'-bipyridin]-6-yl)pentanoate (**C6**) (68.8 mg, 0.15 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 70-30) to afford the desired compound **D6** (63.9 mg, 62%) as a yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ** 7.89 (d, *J* = 7.8 Hz, 1H), 7.73 (s, 1H), 7.53 (s, 1H), 7.49 (s, 1H), 7.41 (s, 1H), 7.31 (d, *J* = 7.7 Hz, 1H), 7.21 (t, *J* = 7.5 Hz, 1H), 7.04 (t, *J* = 7.5 Hz, 1H), 3.65 (s, 3H), 3.54 – 3.50 (m, 2H), 2.41 – 2.37 (m, 2H), 1.84 – 1.81 (m, 4H), 1.45 (s, 9H), 1.44 (s, 9H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ** 174.3, 167.9, 165.3, 163.2, 162.7, 157.2, 155.0, 145.8, 136.8, 133.7, 130.2, 125.3, 123.8, 123.5, 116.7, 115.2, 114.9, 51.4, 38.1, 35.8, 35.2, 33.9, 31.0, 30.4, 30.3, 24.3.

**Elemental Analysis:** calcd for: C<sub>30</sub>H<sub>37</sub>ClN<sub>2</sub>O<sub>2</sub>Pt: C, 52.36. H, 5.42, N, 4.07. Found: C, 52.41. H, 5.37. N, 4.31.

**Chloro(*N,N,6C''*)-(8*S,9R,10R,13S,14R,17S*)-17-((*R*)-4-(4,4'-Di-*tert*-butyl-6'-phenyl-[2,2'-bipyridin]-6-yl)butan-2-yl)-10,13-dimethyldodecahydro-3*H*-cyclopenta[*a*]phenanthrene-3,7,12(2*H,4H*)-trione platinum (D8):**



Following the general procedure **C** using 8*S,9R,10R,13S,14R,17S*-17-((*R*)-4-(4,4'-di-*tert*-butyl-6'-phenyl-[2,2'-bipyridin]-6-yl)butan-2-yl)-10,13-dimethyldodecahydro-3*H*-cyclopenta[*a*]phenanthrene-3,7,12(2*H,4H*)-trione (**C8**) (105.0 mg, 0.15 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 70-

30) to afford the desired compound **D8** (67.0 mg, 48%) as a yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ** 7.94 (d, *J* = 7.7 Hz, 1H), 7.75 (s, 1H), 7.55 (s, 1H), 7.51 (s, 1H), 7.43 (s, 1H), 7.34 (d, *J* = 7.7 Hz, 1H), 7.19 (t, *J* = 8.1 Hz, 1H), 7.06 (t, *J* = 7.5 Hz, 1H), 3.96 (td, *J* = 12.4, 4.8 Hz, 1H), 3.22 (td, *J* = 12.4, 4.8 Hz, 1H), 2.98 – 2.76 (m, 3H), 2.38 – 2.27 (m,




2H), 2.27 – 2.08 (m, 6H), 2.07 – 1.88 (m, 5H), 1.84 – 1.77 (m, 1H), 1.74 – 1.55 (m, 3H), 1.45 (s, 9H), 1.43 (s, 9H), 1.40 (s, 3H), 1.11 (s, 3H), 0.98 (d,  $J = 6.6$  Hz, 3H), 0.88 (t,  $J = 6.8$  Hz, 2H).

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  212.5, 209.2, 208.9, 169.3, 165.3, 163.2, 162.7, 157.0, 155.1, 145.9, 136.9, 133.8, 130.2, 125.2, 123.9, 123.5, 116.6, 115.1, 114.8, 57.1, 51.9, 49.0, 46.8, 46.6, 45.7, 45.0, 42.7, 38.7, 38.0, 36.5, 36.3, 36.0, 35.8, 35.5, 35.2, 30.4, 27.5, 25.2, 22.6, 21.9, 19.0, 14.1, 11.9.

$[\alpha]_{\text{D}}^{25} = -366$  ( $c = 1.4 \cdot 10^{-4}$  M in  $\text{CH}_2\text{Cl}_2$ )

**Elemental Analysis:** calcd for:  $\text{C}_{47}\text{H}_{59}\text{ClN}_2\text{O}_3\text{Pt}$ : C, 60.67. H, 6.39, N, 3.01. Found: C, 60.89. H, 6.41. N, 2.87.

**Chloro(*N,N,6C''*)-4,4'-Di-*tert*-butyl-6-(((1*R*,2*S*,5*R*)-2-isopropyl-5-**



**methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-bipyridine platinum ((-)-D9):**

Following the general procedure **C** using 4,4'-di-*tert*-butyl-6-(((1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-bipyridine ((-)-**C9**) (76.9 mg, 0.15 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 70-30) to afford the desired compound ((-)-**D9**) (86.9 mg, 78%) as a yellow solid.


$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.00 (d,  $J = 2.0$  Hz, 1H), 7.81 (dd,  $J = 7.8$ , 1.2 Hz, 1H), 7.72 (d,  $J = 2.1$  Hz, 1H), 7.52 (d,  $J = 1.6$  Hz, 1H), 7.48 (d,  $J = 1.7$  Hz, 1H), 7.26 (dd,  $J = 7.7$ , 1.5 Hz, 1H), 7.13 (td,  $J = 7.5$ , 1.4 Hz, 1H), 6.98 (td,  $J = 7.4$ , 1.3 Hz, 1H), 5.41 (d,  $J = 17.2$  Hz, 1H), 5.04 (d,  $J = 17.1$  Hz, 1H), 3.43 (td,  $J = 10.5$ , 4.0 Hz, 1H), 2.49 – 2.42 (m, 1H), 2.40 – 2.29 (m, 1H), 1.76 – 1.62 (m, 3H), 1.46 (s, 9H), 1.45 (s, 9H), 1.09 – 1.01 (m, 2H), 1.01 – 0.95 (m, 6H), 0.94 – 0.88 (m, 2H), 0.85 (d,  $J = 7.0$  Hz, 3H).

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  165.9, 165.4, 163.3, 162.7, 156.6, 154.8, 146.1, 137.5, 133.5, 130.0, 123.8, 123.4, 122.0, 117.0, 115.3, 114.9, 80.6, 71.7, 48.2, 40.8, 35.8, 35.5, 34.6, 31.5, 30.4, 30.3, 26.5, 23.6, 22.4, 21.0, 16.6.

$[\alpha]_{\text{D}}^{25} = -248$  ( $c = 1.2 \cdot 10^{-4}$  M in  $\text{CH}_2\text{Cl}_2$ )

**Elemental Analysis:** calcd for:  $\text{C}_{35}\text{H}_{47}\text{ClN}_2\text{OPt}$ : C, 56.63. H, 6.38, N, 3.77. Found: C, 56.45. H, 6.20. N, 3.91.

**Chloro(*N,N,6C''*)-4,4'-Di-*tert*-butyl-6-(((1*S,2R,5S*)-2-isopropyl-5-**



**methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-bipyridine platinum**

**(+)**D9****: Following the general procedure **C** using 4,4'-di-*tert*-butyl-6-(((1*S,2R,5S*)-2-isopropyl-5-methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-bipyridine (**(+)**C9****) (76.9 mg, 0.15 mmol), the residue was purified by flash chromatography on silica gel (heptane-EtOAc, 70-30) to afford the desired compound **(+)**D9**** (86.9 mg, 78%) as a yellow solid.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$  8.00 (d,  $J = 2.0$  Hz, 1H), 7.81 (dd,  $J = 7.8$ , 1.2 Hz, 1H), 7.72 (d,  $J = 2.1$  Hz, 1H), 7.52 (d,  $J = 1.6$  Hz, 1H), 7.48 (d,  $J = 1.7$  Hz, 1H), 7.26 (dd,  $J = 7.7$ , 1.5 Hz, 1H), 7.13 (td,  $J = 7.5$ , 1.4 Hz, 1H), 6.98 (td,  $J = 7.4$ , 1.3 Hz, 1H), 5.41 (d,  $J = 17.2$  Hz, 1H), 5.04 (d,  $J = 17.1$  Hz, 1H), 3.43 (td,  $J = 10.5$ , 4.0 Hz, 1H), 2.49 – 2.42 (m, 1H), 2.40 – 2.29 (m, 1H), 1.76 – 1.62 (m, 3H), 1.46 (s, 9H), 1.45 (s, 9H), 1.09 – 1.01 (m, 2H), 1.01 – 0.95 (m, 6H), 0.94 – 0.88 (m, 2H), 0.85 (d,  $J = 7.0$  Hz, 3H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$  165.9, 165.4, 163.3, 162.7, 156.6, 154.8, 146.1, 137.5, 133.5, 130.0, 123.8, 123.4, 122.0, 117.0, 115.3, 114.9, 80.6, 71.7, 48.2, 40.8, 35.8, 35.5, 34.6, 31.5, 30.4, 30.3, 26.5, 23.6, 22.4, 21.0, 16.6.


$[\alpha]_D^{25} = +258$  ( $c = 1.8 \cdot 10^{-4}$  M in CH<sub>2</sub>Cl<sub>2</sub>)

**Elemental Analysis:** calcd for: C<sub>35</sub>H<sub>47</sub>ClN<sub>2</sub>OPt: C, 56.63. H, 6.38, N, 3.77. Found: C, 56.71. H, 6.21. N, 3.86.

**5. Procedure for the preparation of alkynyl cyclometalated Pt(II) complexes & Product Characterizations**

**General Procedure D:** A mixture of Chloro(*N,N,6C''*)-4,4'-Di-*tert*-butyl-6-alkyl-6'-phenyl-2,2'-bipyridine platinum (0.03 mmol), phenyl acetylene (0.04 mmol) and copper iodide (3.10<sup>-6</sup> mol) in CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>3</sub>N (2/1 v/v mL) or DMF/Et<sub>3</sub>N (2/1 v/v mL) was stirred at room temperature for 12 h. The resultant solution was evaporated to dryness and was purified over preparative chromatography plate on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/Pentane 1/1 v/v) to afford the desired compound.

**Phenyl acetylene (N,N,6C'')-4,4'-Di-tert-butyl-6-dodecyl-6'-phenyl-2,2'-bipyridine platinum (E4):**




Following the general procedure **D** using Chloro(*N,N,6C''*)-4,4'-Di-tert-butyl-6-dodecyl-6'-phenyl-2,2'-bipyridine platinum (**D4**) (1000 mg, 0.136 mmol) the desired complex **E4** was isolated (87.2 mg, 80%).

**<sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>)** δ 8.16 (dd, *J* = 7.6, 1.1 Hz, 1H), 7.83 (d, *J* = 2.0 Hz, 1H), 7.74 – 7.67 (m, 2H), 7.52 (dd, *J* = 4.3, 1.8 Hz, 2H), 7.49 – 7.40 (m, 2H), 7.29 (t, *J* = 7.6 Hz, 2H), 7.24 – 7.08 (m, 3H), 3.72 (t, *J* = 7.7 Hz, 2H), 1.89 (t, *J* = 7.6 Hz, 2H), 1.50 (s, 9H), 1.46 (s, 9H), 1.30 (m, 18H), 0.92 (t, *J* = 6.8 Hz, 3H).

**<sup>13</sup>C NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>)** δ 167.8, 163.9, 163.6, 163.4, 158.3, 155.5, 146.5, 137.9, 137.2, 131.2, 130.5, 129.5, 127.8, 127.8, 124.6, 124.3, 123.8, 123.4, 117.1, 115.3, 115.2, 107.5, 106.8, 41.3, 35.9, 35.2, 31.9, 31.7, 30.2, 30.0, 29.8, 29.7, 29.6, 29.4, 29.2, 22.7, 13.9.

**Elemental Analysis:** calcd for: C<sub>44</sub>H<sub>56</sub>N<sub>2</sub>Pt: C, 65.40. H, 6.99, N, 24.14. Found: C, 65.44. H, 7.19. N, 23.98.

**Phenyl acetylene (N,N,6C'')-5-(4,4'-di-tert-butyl-6'-phenyl-[2,2'-bipyridin]-6-yl)methylpentanoate platinum (E6):**



Following the general procedure **D** using chloro(*N,N,6C''*)-5-(4,4'-di-tert-butyl-6'-phenyl-[2,2'-bipyridin]-6-yl) methyl pentanoate platinum (**D6**) (100 mg, 0.141 mmol) the desired complex **E6** was isolated (65.8 mg, 67%).

**<sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>)** δ 8.11 (dd, *J* = 7.5, 1.4 Hz, 1H), 7.81 (d, *J* = 2.0 Hz, 1H), 7.73 – 7.59 (m, 2H), 7.50 (d, *J* = 2.0 Hz, 1H), 7.48 (d, *J* = 1.4 Hz, 1H), 7.47 – 7.38 (m, 2H), 7.26 (t, *J* = 7.5 Hz, 2H), 7.20 – 7.03 (m, 3H), 3.70 (t, *J* = 7.5 Hz, 2H), 3.56 (s, 3H), 2.30 (t, *J* = 7.5 Hz, 2H), 1.98 – 1.84 (m, 2H), 1.75 (m, 2H), 1.46 (s, 9H), 1.43 (s, 9H).


**<sup>13</sup>C NMR (125 MHz, CD<sub>2</sub>Cl<sub>2</sub>)** δ 173.7, 167.0, 163.9, 163.6, 163.6, 158.4, 155.4, 146.4, 137.7, 137.1, 131.1, 130.5, 129.3, 127.8, 124.6, 124.2, 123.7, 123.4, 117.2, 115.3, 115.2, 107.4, 106.7, 51.1, 40.8, 35.8, 33.8, 30.9, 30.1, 29.9, 24.3.

**Elemental Analysis:** calcd for: C<sub>38</sub>H<sub>42</sub>N<sub>2</sub>O<sub>2</sub>Pt: C, 60.54, H, 5.62, N, 3.72. Found: C, 60.31. H, 5.78. N, 3.54.

Phenyl

acetylene

(*N,N,6C''*)-4,4'-Di-*tert*-butyl-6-(((1*R*,2*S*,5*R*)-2-isopropyl-5-



methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-bipyridine platinum ((-)-**E9**): Following the general procedure **D** using Chloro(*N,N,6C''*)-4,4'-Di-*tert*-butyl-6-(((1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-bipyridine platinum ((-)-**D9**) (35.1 mg, 0.047 mmol) the desired complex (-)-**E9** was isolated (29.2 mg, 83%).

<sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 8.05 (dd, *J* = 7.5, 1.1 Hz, 1H), 7.99 (d, *J* = 1.8 Hz, 1H), 7.82 (d, *J* = 1.8 Hz, 1H), 7.67 (dd, *J* = 15.0, 1.3 Hz, 2H), 7.48 (d, *J* = 1.3 Hz, 1H), 7.48 – 7.37 (m, 2H), 7.25 (t, *J* = 7.6 Hz, 2H), 7.17 – 7.04 (m, 3H), 5.50 (d, *J* = 17.0 Hz, 1H), 5.11 (d, *J* = 17.0 Hz, 1H), 3.33 (td, *J* = 10.5, 4.1 Hz, 1H), 2.33 – 2.27 (m, 2H), 1.46 (s, 9H), 1.43 (s, 9H), 1.04 (m, 1H), 0.93 (d, *J* = 7.0 Hz, 3H), 0.79 (d, *J* = 7.0 Hz, 3H), 0.60 (d, *J* = 6.4 Hz, 3H).

<sup>13</sup>C NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 165.1, 164.7, 164.4, 158.6, 155.6, 147.2, 139.0, 137.7, 131.7, 131.2, 129.9, 128.5, 125.3, 124.5, 124.1, 122.3, 122.3, 118.2, 116.0, 115.7, 109.7, 80.9, 74.6, 48.8, 41.0, 36.5, 36.1, 35.1, 31.8, 30.8, 30.6, 27.1, 24.2, 22.3, 21.2, 17.0.


[α]<sub>D</sub><sup>25</sup> = -167 (c = 1.8 · 10<sup>-4</sup> M in CH<sub>2</sub>Cl<sub>2</sub>).

**Elemental Analysis:** calcd for: C<sub>43</sub>H<sub>52</sub>N<sub>2</sub>O<sub>2</sub>Pt, ¼ CH<sub>2</sub>Cl<sub>2</sub>: C, 62.65. H, 6.38, N, 3.38. Found: C, 62.45. H, 6.45. N, 3.31.

Phenyl

acetylene

(*N,N,6C''*)-4,4'-Di-*tert*-butyl-6-(((1*S*,2*R*,5*S*)-2-isopropyl-5-



methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-bipyridine platinum ((+)-**E9**): Following the general procedure **D** using Chloro(*N,N,6C''*)-4,4'-Di-*tert*-butyl-6-(((1*S*,2*R*,5*S*)-2-isopropyl-5-methylcyclohexyl)oxy)methyl)-6'-phenyl-2,2'-bipyridine platinum ((+)-**D9**) (36.4 mg, 0.049 mmol) the desired complex (+)-**E9** was isolated (28.7 mg, 79%).

<sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 8.06 (d, *J* = 7.5 Hz, 1H), 8.00 (s, 1H), 7.83 (s, 1H), 7.68 (d, *J* = 15.0 Hz, 2H), 7.56 – 7.37 (m, 3H), 7.26 (t, *J* = 7.6 Hz, 3H), 7.18 – 7.07 (m, 3H), 5.51 (d, *J* = 17.0 Hz, 1H), 5.12 (d, *J* = 17.0 Hz, 1H), 3.34 (td, *J* = 10.5, 4.1 Hz, 1H), 2.33 – 2.27 (m, 2H), 1.47 (s, 9H), 1.44 (s, 9H), 1.04 (m, 1H), 0.94 (d, *J* = 7.0 Hz, 3H), 0.79 (d, *J* = 7.0 Hz, 4H), 0.61 (d, *J* = 6.4 Hz, 3H).


<sup>13</sup>C NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 165.1, 164.7, 164.4, 158.6, 155.6, 147.2, 139.0, 137.7, 131.7, 131.2, 129.9, 128.5, 125.3, 124.5, 124.1, 122.3, 122.3, 118.2, 116.0, 115.7, 109.7, 80.9, 74.6, 48.8, 41.0, 36.5, 36.1, 35.1, 31.8, 30.8, 30.6, 27.1, 24.2, 22.3, 21.2, 17.0.

[α]<sub>D</sub><sup>25</sup> = +181 (c = 2.5 · 10<sup>-4</sup> M in CH<sub>2</sub>Cl<sub>2</sub>)

**Elemental Analysis:** calcd for: C<sub>43</sub>H<sub>52</sub>N<sub>2</sub>OPt, ¼ CH<sub>2</sub>Cl<sub>2</sub>: C, 62.65. H, 6.38, N, 3.38. Found: C, 62.45. H, 6.45. N, 3.31

## 6. X-ray crystallographic data

The numbering of the .cif files have been adapted to obtained the labelling presented below:



**Table S1.** Selected Bond Lengths [Å], Angles [deg], and Torsion Angle [deg] for **D1**, **D2**, **D3**, **D5**, **D6**, **(+)-D9** and **(-)-D9**.


		<b>D1</b>	<b>D2</b>	<b>D3</b>	<b>D5</b>	<b>D6</b>	<b>(+)-D9</b>	<b>(-)-D9</b>
Bond length [Å]	Pt1-N2	1.963(4)	1.966(3)	1.961(3)	1.968(3)	1.961(3)	1.989(9)	1.924(8)
	Pt1-C1	1.986(5)	1.989(4)	1.979(4)	1.987(5)	1.993(4)	2.012(11)	2.024(9)
	Pt1-N1	2.206(4)	2.194(3)	2.312(3)	2.204(4)	2.204(4)	2.182(9)	2.193(8)
Angles [deg]	N2-Pt1-C1	82.04(18)	82.26(15)	81.83(15)	82.07(17)	82.16(16)	81.9(5)	81.4(5)
	N2-Pt1-N1	78.31(16)	78.20(13)	77.28(12)	78.37(14)	78.25(13)	78.9(4)	78.2(4)
	C1-Pt1-N1	160.34(18)	160.27(15)	159.05(14)	160.27(16)	160.41(16)	160.4(5)	159.1(4)
	N2-Pt1-Cl1	175.14(12)	171.01(10)	174.51(10)	174.87(11)	174.52(10)	175.2(3)	174.8(4)
	C1-Pt1-Cl1	93.16(14)	93.02(12)	93.78(12)	93.47(13)	92.97(13)	94.2(4)	95.1(4)
	N1-Pt1-Cl1	106.49(11)	106.71(9)	107.17(8)	106.18(10)	106.59(9)	105.2(3)	105.6(3)
Torsion angle [deg]	Pt1-N1-C5-C4	-2.30(5)	-6.80(4)	-28.50(4)	-3.00(4)	-1.00(4)	0.6(11)	0.8(10)
	Pt1-N2-C4-C5	-0.50(5)	5.90(5)	-1.00(5)	-6.00(5)	-0.80(5)	5.9(13)	-2.2(10)
	Pt1-N2-C3-C2	0.80(5)	-4.20(4)	4.40(4)	2.10(4)	-0.20(4)	-1.4(13)	-1.8(10)
	C3-C2-C1-Pt1	-0.70(5)	-0.60(5)	-6.10(4)	-0.70(5)	0.80(4)	1.1(13)	-4.2(10)

## 7. Additional photophysical data


**Table S2.** Absorption and emission data for platinum chloro complexes **D1**, **D2**, **D3**, **D4**, **D6**, **D8**, (-)-**D9**, (+)-**D9**.

	$\lambda_{\text{abs}}^{\text{a}} / \text{nm} (\epsilon \cdot 10^{-3} / \text{M}^{-1}\text{cm}^{-1})$	$\lambda_{\text{em}}^{\text{b}} / \text{nm} (\tau / \mu\text{s} ; \Phi)^{\text{c}}$
<b>D1</b>	284 (25.6), 329 (13.8), 360 (6.9), 412 (2.2)	544 (0.021)
<b>D2</b>	283 (25.5), 329 (13.4), 359 (7.2), 410 (2.1)	544 (0.020)
<b>D3</b>	266 (23.0), 284 (24.3), 324 (1.35), 366 (5.2), 404 (2.5)	-
<b>D4</b>	285 (26.5), 329 (13.4), 360 (6.9), 410 (2.2)	593 (< 0.01)
<b>D6</b>	284 (27.1), 328 (13.8), 360 (6.9), 410 (2.3)	566 (0.038)
<b>D7</b>	285 (26.5), 329 (13.3), 360 (7.0), 410 (2.2)	570 (0.062)
<b>(-)-D8</b>	282 (22.3), 328 (11.9), 360 (6.9), 411 (2.2)	567 (0.029)
<b>(+)-D8</b>	282 (22.3), 328 (11.9), 360 (6.9), 411 (2.2)	567 (0.029)


<sup>a</sup> Measured in  $\text{CH}_2\text{Cl}_2$  solution at 298 K ( $C \approx 10^{-5}$  M). <sup>b</sup> In degassed  $\text{CH}_2\text{Cl}_2$  solution at 298 K ( $C \approx 10^{-5}$  M). <sup>c</sup> With  $\text{Ru}(\text{bpy})_3\text{Cl}_2$  as reference.



**Figure S1.** Absorption and emission spectra in  $\text{CH}_2\text{Cl}_2$  at 298 K ( $C \approx 10^{-5}$  M) of the **D** series of complexes ( $\lambda_{\text{ex}} = 400$  nm).




**Figure S2.** Excitation spectra in degassed  $\text{CH}_2\text{Cl}_2$  at 298 K of a) **D1**, **D2**, **D4** and **D6** ( $\lambda_{\text{em}} = 550 \text{ nm}$ ) and b) **E4**, **E6**, **(-)-E9** and **(+)-E9** ( $\lambda_{\text{em}} = 584 \text{ nm}$ ).




**Figure S3.** Emission decay curves of **E4**, **E6**, **(-)-E9** and **(+)-E9** in degassed  $\text{CH}_2\text{Cl}_2$  at 298 K,  $\lambda_{\text{ex}} = 375 \text{ nm}$ .

**Table S2.** Fitting of luminescence decays in degassed dichloromethane at 298 K for complexes **E4**, **E6**, **(-)-E9** and **(+)-E9** ( $C \approx 10^{-5}$  M,  $\lambda_{ex} = 375$  nm). Experimental decays in green, monoexponential fits in blue and residual traces in red.


**E4**




**E6**



**(-)-E9**



**(+)-E9**







## 8. References



1. G. A. Crosby and J. N. Demas, *The Journal of Physical Chemistry*, 1971, **75**, 991.
2. K. A. Teegardin and J. D. Weaver, *Org. Synth.*, 2018, **95**, 29.
3. (a) X. Lu, B. Xiao, L. Liu and Y. Fu, *Chem. Eur. J.*, 2016, **22**, 11161; (b) F. Toriyama, J. Cornella, L. Wimmer, T.-G. Chen, D. D. Dixon, G. Creech and P. S. Baran, *J. Am. Chem. Soc.*, 2016, **138**, 11132; (c) W. M. Cheng, R. Shang, M. C. Fu and Y. Fu, *Chem. Eur. J.*, 2017, **23**, 2537.
4. C. Zheng, Y. Wang, Y. Xu, Z. Chen, G. Chen and S. H. Liang, *Org. Lett.*, 2018, **20**, 4824.
5. H. Li, C. P. Breen, H. Seo, T. F. Jamison, Y.-Q. Fang and M. M. Bio, *Org. Lett.*, 2018, **20**, 1338.
6. T. Brandhofer and O. G. Mancheño, *ChemCatChem*, 2019, **11**, 3797.
7. S. Ni, N. M. Padial, C. Kingston, J. C. Vantourout, D. C. Schmitt, J. T. Edwards, M. M. Kruszyk, R. R. Merchant, P. K. Mykhailiuk, B. B. Sanchez, S. Yang, M. A. Perry, G. M. Gallego, J. J. Mousseau, M. R. Collins, R. J. Cherney, P. S. Lebed, J. S. Chen, T. Qin and P. S. Baran, *J. Am. Chem. Soc.*, 2019, **141**, 6726.
8. T. Qin, L. R. Malins, J. T. Edwards, R. R. Merchant, A. J. E. Novak, J. Z. Zhong, R. B. Mills, M. Yan, C. Yuan, M. D. Eastgate and P. S. Baran, *Angew. Chem. Int. Ed.*, 2017, **56**, 260.

## 9. Copy of the NMR spectrum



# B1





# B2





### B3





# B4





# B5



B6





B7









B8





**(-)-B9**





(+)-B9





C1





C2





C3



# C4





C5









C6





C7





C8





**(-)-C9**





(+)-C9





# C10



C11





# C12









D1





D2



# D3





# D4









D6



D8





**(-)-D9**









(+)-D9





# E4



E6



(-)-E9



(+)-E9

